The immune microenvironment represents a source of resistance to MAPK pathway inhibitors also via an increased number of tumor-associated macrophages, and TNFα and MITF (microphthalmia transcription factor) expression, observed in BRAF-mutant melanomas [70]. Here, BRAF is linked to neoplasm.